The Impact of Sodium–Glucose Cotransporter–2 Inhibitors on Atrial Electromechanical Conduction Time

Sodyum–Gluokz Kotransporter–2 İnhibitörlerinin Atriyal Elektromekanik İleti Zamanı Üzerine Etkisi

ABSTRACT

Objective: This study aims to explore the impact of sodium–glucose cotransporter–2 (SGLT–2) inhibitors, a newer class of oral antidiabetic drugs, on atrial electromechanical delay (EMD) in patients with type 2 diabetes mellitus (DM). This is particularly relevant given the significantly higher incidence of atrial fibrillation (AF) in diabetic patients compared to the general population. Atrial electromechanical delay is recognized as an important factor influencing the development of atrial fibrillation.

Methods: This study included 30 type 2 DM patients (53.3% female, mean age 60.07 ± 10.03 years), initiating treatment with SGLT–2 inhibitors. The patients were assessed using echocardiography at baseline and again at 6 months, focusing on basic echocardiographic parameters and atrial electromechanical delay times (EMD) measured via tissue Doppler imaging.

Results: No significant changes were observed in intra-atrial EMD times. However, significant reductions were noted in inter-atrial EMD times, decreasing from 15.13 ± 5.87 ms to 13.20 ± 6.12 ms (P = 0.029). Statistically significant shortening occurred in lateral pulmonary acceleration (PA) times (from 58.73 ± 6.41 ms to 54.37 ± 6.97 ms, P < 0.001), septal PA times (from 50.90 ± 6.02 ms to 48.23 ± 5.0, and tricuspid PA times (from 43.60 ± 6.28 ms to 41.30 ± 5.60 ms, P = 0.003). Additionally, there was a significant reduction in the E/e' ratio from 8.13 ± 4.0 to 6.50 ± 2.37 (P = 0.003).

Conclusion: SGLT–2 inhibitors might positively influence atrial electromechanical conduction, reducing DM-related functional impairments and the risk of arrhythmias, particularly AF.

Keywords: Atrial electromechanical delay, atrial fibrillation, diabetes mellitus, SGLT–2 inhibitors

ÖZET

Amaç: Diabetik hastalarda atrial fibrilasyon (AF) sıklığının normal popülasyona göre anlamlı derecede arttığı gösterilmiştir. Atrial elektromekanik geceğme, atriyal fibrilasyonun önemli bir belirleyici olarak bilinir. Bu çalışmada tip 2 diyetetik melitusu (DM) hastaarda göre yeni oral anti-diyabetik ilaçlar olan sodyum–glukoz kotransporter–2 (SGLT–2) inhibitörlerinin atriyal elektromekanik geceğme (EMG) zamanı üzerinde etkilerini araştırılmış amaçlanmaktadır.


Bulgular: İntra-atrial EMG zamanlarında anlamlı azalma izlenmemek, inter- atrial EMG zamanlarında anlamlı azalma izlendi, 15,13 ± 5,87 ms olan interatriyal EMG sürelerinin kontrolde 13,20 ± 6,12 ms'e gerilediği (P = 0,029) bulundu. Lateral PA sürelerinde (58,73 ± 6,41 ms'den 54,37 ± 6,97 ms'e, P < 0,001), septal PA sürelerinde (50,90 ± 6,02 ms'den 48,23 ± 5,88 ms'e, P < 0,001) ve trüküspit PA sürelerinde (43,60 ± 6,28 ms'den 41,30 ± 5,60 ms'ye, P = 0,003) istatistiksel olarak anlamlı kısalma gözlemdi. E/e'de değerlerinde 8,13 ± 4,0'den 6,50 ± 2,37'e anlamlı azalma görüldü (P = 0,003).

Sonuç: SGLT–2 inhibitörleri atriumun elektromekanik iletiği üzerinde iyileştirici etkilerle sahip olabilir ve böylece SGLT–2 inhibitörleri, DM ilişkili atriumlardaki fonksiyonel bozuluk ve başta AF olmak üzere atriatal akımların koruyabilir.

Anahtar Kelimeler: Atriyal elektromekanik geceğme, atrial fibrilasyon, diabetes mellitus, SGLT–2 inhibitörleri

ORIGINAL ARTICLE

KLİNİK ÇALIŞMA

Enes Çelik1
Murat Kerkütlüoğlu1
Murat Şahin2
Ekrem Aksu1
Akif Serhat Balçıoğlu1

1Department of Cardiology, Kahramanmaraş Sütçü İmam University, Faculty of Medicine, Kahramanmaraş, Türkiye
2Department of Endocrinology, Kahramanmaraş Sütçü İmam University, Faculty of Medicine, Kahramanmaraş, Türkiye

Corresponding author:
Enes Çelik
enescelikmd@gmail.com

Received: September 11, 2023
Accepted: January 28, 2024


DOI:10.5543/tkda.2024.27546

Available online at archivestsc.com.

Content of this journal is licensed under a Creative Commons Attribution - NonCommercial-NoDerivatives 4.0 International License.
Diabetes mellitus (DM) is a widespread chronic disease closely associated with increased cardiovascular morbidity and mortality. Type 2 diabetes is independently associated with increased risks of both atrial fibrillation (AF) and ischemic stroke. Extensive evidence from preclinical and clinical studies shows that diabetes is linked to cardiac fibrosis and that these fibrotic alterations play a crucial role in the onset and persistence of AF. Individuals with AF and diabetes experience an annual increase in stroke risk by 2% to 3.5%. In addition to blood sugar management, sodium–glucose cotransporter-2 (SGLT2) inhibitors—newer oral anti-diabetic medications—have demonstrated positive impacts on cardiovascular mortality and hospitalizations rates for heart failure (HF). Non-invasive methods, such as measuring atrial electromechanical delay (EMD) times through tissue Doppler imaging (TDI) via transthoracic echocardiography, are commonly used to assess the risk of AF. EMD time, indicative of atrial conduction heterogeneity, is measured from the start of electrical activity to the onset of force in the myocardium. It is established that prolonged atrial EMD times, as observed through TDI, are indicators of AF.

This study involved 30 patients with type 2 diabetes mellitus (DM) who, due to inadequate blood sugar control with existing antidiabetic therapies, were selected to begin treatment with an SGLT-2 inhibitor. The objective was to assess changes in atrial EMD times by analyzing echocardiography and TDI data before and after six months of treatment with an SGLT-2 inhibitor.

Materials and Methods

Study Population

This study was designed as a prospective observational study. It included 30 type 2 DM patients from our clinics who required additional treatment with an SGLT-2 inhibitor because their current antidiabetic medications were insufficient for optimal blood sugar management. No changes were made to their existing treatments except for the introduction of the SGLT-2 inhibitor. Patients with a history of AF or those who experienced an AF episode during the study, had any acute coronary syndrome in the previous year, suffered from heart failure with a reduced ejection fraction (less than 50%), showed signs of heart failure, had moderate to severe heart valve disease, cardiomyopathies, or were undergoing hemodialysis were excluded from the study. This study involved 30 patients with type 2 diabetes mellitus (DM) who, due to inadequate blood sugar control with existing antidiabetic therapies, were selected to begin treatment with an SGLT-2 inhibitor. The objective was to assess changes in atrial EMD times by analyzing echocardiography and TDI data before and after six months of treatment with an SGLT-2 inhibitor.

Laboratory and demographic data for the patients were collected. Echocardiographic assessments were performed on all patients before and after the treatment by the same cardiologist, and atrial electromechanical delay times were measured using tissue Doppler.

The study adhered to the ethical guidelines outlined in the Declaration of Helsinki and received approval from the Medical Research Ethics Committee of Kahramanmaraş Sütçü İmam University (Approval Date: June 8, 2021; Approval Number: 2021/20). Each patient provided written informed consent.

Echocardiography

Transthoracic echocardiography was conducted using a GE Vivid E9 device (GE Healthcare, Europe). Routine assessments included measurements of heart chamber dimensions, thickness of the left ventricular (LV) posterior wall and interventricular wall, LV systolic (left ventricular ejection fraction, LVEF) and diastolic functions, and the anatomical and functional characteristics of the heart valves. Continuous single-lead electrocardiographic monitoring was performed throughout the echocardiographic examination. Dimensions and areas of both atria, septal and diastolic diameters of the right ventricle, end-systolic and end-diastolic areas, tricuspid annular plane systolic excursion (TAPSE), systolic pulmonary artery pressures, mitral inflow velocities of E and A waves, and tissue Doppler measurements were recorded in accordance with American Society of Echocardiography standards. LVEF was calculated using the biplane Simpson’s method.

Tissue Doppler Echocardiography

Tissue Doppler echocardiography was executed using a 3.5–4.0 MHz transducer. After setting the Nyquist limits to 15–20 cm/s, data were collected from the LV lateral mitral annulus, LV septal mitral annulus, and right ventricular tricuspid annulus using Doppler in the apical four–chamber view. Peak systolic (s/Sm), late diastolic (a’/Am), early diastolic (e’/Em) velocities, isovolumetric contraction time, isovolumetric relaxation time (IVRT), and ejection times were recorded from the mitral and tricuspid annulii. Atrial electromechanical conduction time (PA) was measured from the onset of the concurrent electrocardiographic P wave to the onset of the late diastolic wave on tissue Doppler. Measurements were taken at the septal mitral annulus (septal PA), lateral mitral annulus (lateral PA), and right ventricular tricuspid annulus (tricuspid PA) (Figure 1).
were enrolled in the study. In a similar study on EMD, the interatrial EMD times were used parameters to evaluate atrial electromechanical delay. Sample sizes were determined with a focus on interatrial EMD, left intra-atrial EMD and interatrial EMD. Therefore, a sample size of 27 was determined to achieve 80% statistical power. From those approximately 29.65 and 26.96. Therefore, a sample size of 27 was used parameters to evaluate atrial electromechanical delay.

Results

The basic characteristics of the participants are summarized in Table 1. The study included 30 patients with type 2 DM, of whom 14 (46.7%) were male and 16 (53.3%) were female. These patients were initiating treatment with SGLT-2 inhibitors. The mean age of the patients was 60.07 ± 10.03 years. A total of 20 (66.7%) patients had concomitant hypertension, 2 (6.7%) had a history of cerebrovascular accidents, and 10 (33.3%) had coronary artery disease. Of the participants, 25 (83.3%) were prescribed dapagliflozin and 5 (16.6%) empagliflozin. Table 2 details the biochemical profiles of the patients at baseline and after 24 weeks of SGLT-2 inhibitor therapy. The results showed no significant changes in estimated Glomerular Filtration Rate (eGFR), creatinine, Blood Urea Nitrogen (BUN), sodium, potassium, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), or gamma-glutamyl transferase (GGT) levels. However, there was a significant reduction in HbA1c, decreasing from 9.33 ± 1.41% to 8.14 ± 1.39% (P < 0.001). Similarly, basal fasting plasma glucose (FPG) levels decreased from 207.8 ± 77.7 mg/dL to 180.0 ± 62.1 mg/dL after 24 weeks of SGLT-2 inhibitor treatment (P = 0.035). Baseline alanine aminotransferase (ALT) levels also decreased from 24.1 ± 14.9 U/L to 20.4 ± 10.3 U/L over six months (P = 0.027). When comparing the baseline echocardiographic data to that at six months post-treatment, no significant changes were observed in the aortic root diameter, LV end-diastolic diameter, interventricular septum thickness, posterior wall thickness, mitral inflow E wave, TAPSE, LVEF, mitral inflow A wave, or pulmonary artery pressure. However, there was a significant increase in the E/A ratio, from 0.72 ± 0.14 to 0.80 ± 0.23 (P = 0.02). The LA area, measured in the apical four chambers (A4C), changed from 15.00 ± 4.04 cm² before treatment to 14.72 ± 3.68 cm² post-treatment, with no significant difference detected. Heart rate measurements were taken with a simultaneous surface electrocardiogram (ECG) during echocardiographic evaluations. Heart rate decreased significantly from a baseline of 83.93 ± 13.25 beats per minute to 76.50 ± 11.44 beats per minute at the 6-month evaluation (P < 0.001). A significant reduction was also noted in the E/E’ ratio, from 8.13 ± 4.0 to 6.50 ± 2.37 (P = 0.003) (Table 3). Tissue Doppler data, compared at baseline and six months, is presented in Table 4. Statistically significant reductions were observed in lateral pulmonary acceleration (PA) times (58.73 ± 6.41 ms to 54.37 ± 6.97 ms, P < 0.001), septal PA times (from 50.90 ± 6.02 ms to 48.23 ± 5.88 ms, P < 0.001), and tricuspid PA times (from 43.60 ± 6.28 ms to 41.30 ± 5.60 ms, P = 0.003). When comparing interatrial and intra-atrial EMD times, a reduction was observed in interatrial EMD times, which decreased from 15.13 ± 5.87 ms initially to 13.20 ± 6.12 ms at the 6-month follow-up (P = 0.029). No significant changes were noted in intra-atrial or left interatrial EMD times.
Table 2. Laboratory Findings

<table>
<thead>
<tr>
<th>Biochemical Parameters</th>
<th>n</th>
<th>Pre-Treatment</th>
<th>Post-Treatment</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>eGFR (mL/min/1.73 m²)</td>
<td>30</td>
<td>87.4 ± 15.6</td>
<td>86.8 ± 17.1</td>
<td>0.757</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>30</td>
<td>0.83 ± 0.15</td>
<td>0.83 ± 0.20</td>
<td>0.821</td>
</tr>
<tr>
<td>BUN (mg/dL)</td>
<td>29</td>
<td>13.57 ± 2.59</td>
<td>14.06 ± 3.69</td>
<td>0.296</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>27</td>
<td>9.33 ± 1.41</td>
<td>8.14 ± 1.39</td>
<td>0.001</td>
</tr>
<tr>
<td>Fasting Plasma Glucose (mg/dL)</td>
<td>30</td>
<td>207.8 ± 77.7</td>
<td>180.0 ± 62.1</td>
<td>0.035</td>
</tr>
<tr>
<td>Total Cholesterol (mg/dL)</td>
<td>21</td>
<td>175.0 ± 60.1</td>
<td>158.1 ± 40.2</td>
<td>0.159</td>
</tr>
<tr>
<td>LDL (mg/dL)</td>
<td>28</td>
<td>109.8 ± 44.6</td>
<td>95.0 ± 29.4</td>
<td>0.062</td>
</tr>
<tr>
<td>HDL (mg/dL)</td>
<td>23</td>
<td>41.0 ± 8.1</td>
<td>42.2 ± 9.3</td>
<td>0.445</td>
</tr>
<tr>
<td>Sodium (mmol/L)</td>
<td>30</td>
<td>138.5 ± 3.1</td>
<td>138.8 ± 3.3</td>
<td>0.556</td>
</tr>
<tr>
<td>Potassium (mmol/L)</td>
<td>30</td>
<td>4.60 ± 0.34</td>
<td>4.57 ± 0.36</td>
<td>0.423</td>
</tr>
<tr>
<td>LDH (mg/dL)</td>
<td>27</td>
<td>206.8 ± 32.3</td>
<td>206.0 ± 26.7</td>
<td>0.887</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>30</td>
<td>20.1 ± 7.9</td>
<td>18.8 ± 5.6</td>
<td>0.206</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>30</td>
<td>24.1 ± 14.9</td>
<td>20.4 ± 10.3</td>
<td>0.027</td>
</tr>
<tr>
<td>GGT (U/L)</td>
<td>26</td>
<td>34.8 ± 24.8</td>
<td>34.3 ± 25.8</td>
<td>0.672</td>
</tr>
</tbody>
</table>

ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; BUN, Blood Urea Nitrogen; eGFR, Estimated Glomerular Filtration Rate; GGT, Gamma Glutamyl Transferase; HbA1c, Glycosylated Hemoglobin; HDL, High-Density Lipoprotein; LDH, Lactate Dehydrogenase; LDL, Low-Density Lipoprotein. Data are presented as mean ± standard deviation.

Table 3. Echocardiographic Parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Pre-Treatment</th>
<th>Post-Treatment</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aortic Root (mm)</td>
<td>21.30 ± 2.38</td>
<td>21.37 ± 2.41</td>
<td>0.677</td>
</tr>
<tr>
<td>LVDD (mm)</td>
<td>46.03 ± 5.54</td>
<td>45.80 ± 5.70</td>
<td>0.379</td>
</tr>
<tr>
<td>IVS (mm)</td>
<td>11.23 ± 1.61</td>
<td>11.07 ± 1.38</td>
<td>0.096</td>
</tr>
<tr>
<td>PW (mm)</td>
<td>10.07 ± 1.23</td>
<td>9.73 ± 1.08</td>
<td>0.023</td>
</tr>
<tr>
<td>E (m/s)</td>
<td>0.62 ± 0.13</td>
<td>0.64 ± 0.14</td>
<td>0.238</td>
</tr>
<tr>
<td>A (m/s)</td>
<td>0.87 ± 0.17</td>
<td>0.83 ± 0.18</td>
<td>0.065</td>
</tr>
<tr>
<td>E/A</td>
<td>0.72 ± 0.14</td>
<td>0.80 ± 0.23</td>
<td>0.021</td>
</tr>
<tr>
<td>E/e'</td>
<td>8.13 ± 4.0</td>
<td>6.50 ± 2.37</td>
<td>0.003</td>
</tr>
<tr>
<td>TAPSE (mm)</td>
<td>26.53 ± 3.04</td>
<td>26.70 ± 3.03</td>
<td>0.556</td>
</tr>
<tr>
<td>Ejection Fraction (%)</td>
<td>59.00 ± 5.68</td>
<td>59.10 ± 5.16</td>
<td>0.756</td>
</tr>
<tr>
<td>LA Area in A4C (cm²)</td>
<td>15.00 ± 4.04</td>
<td>14.72 ± 3.68</td>
<td>0.230</td>
</tr>
<tr>
<td>Heart Rate (beats/min)</td>
<td>83.93 ± 13.25</td>
<td>76.50 ± 11.44</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PAP (mmHg)</td>
<td>6.50 ± 9.66</td>
<td>6.33 ± 10.08</td>
<td>0.899</td>
</tr>
</tbody>
</table>

A, Late Transmitial Flow Velocity; A4C, Apical 4 Spaces; E, Early Transmitial Flow Velocity; e', Early Diastolic Mitral Annular Velocity; IVS, Interventricular Septum; LVDD, Left Ventricular End-Diastolic Diameter; LVSD, Left Ventricular End-Systolic Diameter; PAP, Pulmonary Artery Pressure; PW, Posterior Wall; TAPSE, Tricuspid Annular Plane Systolic Excursion. Data are presented as mean ± standard deviation.

Table 4. Atrial Electromechanical Conduction Times

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Pre-Treatment</th>
<th>Post-Treatment</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lateral PA (ms)</td>
<td>58.73 ± 6.40</td>
<td>54.37 ± 6.97</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Septal PA (ms)</td>
<td>50.90 ± 6.02</td>
<td>48.23 ± 5.87</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Tricuspid PA (ms)</td>
<td>43.60 ± 6.28</td>
<td>41.30 ± 5.59</td>
<td>0.003</td>
</tr>
<tr>
<td>Right Intra-Atrial EMD (ms)</td>
<td>7.13 ± 5.48</td>
<td>6.67 ± 5.27</td>
<td>0.527</td>
</tr>
<tr>
<td>Left Intra-Atrial EMD (ms)</td>
<td>7.83 ± 4.48</td>
<td>7.30 ± 6.43</td>
<td>0.642</td>
</tr>
<tr>
<td>Interatrial EMD (ms)</td>
<td>15.13 ± 5.87</td>
<td>13.20 ± 6.12</td>
<td>0.029</td>
</tr>
</tbody>
</table>

EMD, Electromechanical Delay; PA, Atrial Electromechanical Conduction Time; SGLT-2, Sodium-Glucose Cotransporter-2. Data are presented as mean ± standard deviation.
In this study, we investigated the effects of SGLT-2 inhibitors on atrial EMD time, which is a predictor of AF development in patients with type 2 DM. SGLT-2 inhibitors were added to the regimen of patients who could not achieve adequate glycemic control with existing oral antidiabetic medications. After comparing tissue Doppler data before and 6 months post-treatment, our study demonstrated a significant reduction in interatrial EMD times from baseline.

AF is more common in patients with DM, due to a variety of complex mechanisms including structural and autonomic remodeling, electrical remodeling, and chronic atrial inflammation. Stroke, a major complication of AF, poses a higher risk in patients with both AF and DM than in non-diabetic AF patients. With the rising incidence of DM in recent years, the prevalence and complications of AF are also expected to increase, making early detection and prevention of these conditions critical. Parameters linked to the development and recurrence of AF can be non-invasively assessed using transthoracic echocardiography. The E/e' ratio correlates with LA pressure; an E/e' greater than 15 usually indicates an LA pressure exceeding 15 mmHg. Additionally, an E/e' ratio over 15 in patients with a history of acute myocardial infarction is associated with increased mortality. Increased E/e' ratios, atrial EMD times, and LA enlargement are known to be linked to the recurrence of AF. In the study by Maragkoudakis et al., echocardiographic evaluations of 30 type 2 DM patients with symptomatic heart failure were conducted 30 days after dapagliflozin was added to their treatment. Following dapagliflozin treatment, the post-treatment E/e' ratio was reduced compared to baseline values, decreasing from 12.4 ± 1.6 to 10.4 ± 1.3, (P < 0.001). In another study, a 24-week course of dapagliflozin treatment was shown to enhance diastolic reserve, although it did not significantly affect the E/e' ratio compared to baseline. In our study, examinations performed six months after starting SGLT-2 inhibitor therapy showed a reduction in the E/e' ratio, which decreased from 8.1 ± 4.0 prior to treatment to 6.5 ± 2.3 after six months of therapy (P = 0.003).

Echocardiographic evaluation of atrial EMD time indicates atrial conduction heterogeneity, defined as the interval between the onset of electrical activity and the generation of force in the myocardium. EMD duration is a measure of both the electrical and functional continuity of atrial myocytes, assessing atrial conduction properties directly associated with AF. It can be determined using TDI and serves as a valuable parameter. It has been demonstrated that paroxysmal AF is linked to increased latency in both interatrial and intraatrial conduction. Moreover, prolonged PA periods have been shown to predict the development of new AF. For instance, Akyel et al. reported that diabetic patients exhibited longer mitral PA durations compared to a control group, with measures of 76.4 ± 15.0 ms for controls versus 86.3 ± 11.7 ms for diabetics (P < 0.001). Additionally, Demir et al. found that patients with type 2 DM had longer mitral annulus lateral PA times and greater intra-atrial and interatrial EMD compared to healthy controls. In our study, we found that after treatment with an SGLT-2 inhibitor, the basal values of mitral annulus lateral PA times significantly decreased from 58.73 ± 6.40 ms to 54.37 ± 6.97 ms (P < 0.001). While diastolic functions were normal in the patient groups in these studies, our research detected a minor left ventricular diastolic dysfunction, a crucial indicator of subclinical cardiac involvement in diabetes patients.

SGLT-2 inhibitors, oral diabetes medications that prevent glucose reabsorption in renal proximal tubules and enhance urine sodium and fluid excretion, thereby reducing intravascular volume, have been initially developed as glucose-lowering agents. These inhibitors reduce hospitalizations and cardiovascular deaths from HF in various populations, including those with type 2 diabetes, renal failure, HF, and cardiovascular disease. The EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients – Removing Excess Glucose) study, a randomized, double-blind, placebo-controlled trial involving 7,020 individuals with type 2 diabetes, was the first to investigate the cardiovascular effects of SGLT-2 inhibitors. After a median follow-up of 3.1 years, the primary endpoint of this study—a composite of myocardial infarction, stroke, and cardiovascular death—was significantly lower. The study also noted a 35% reduction in hospitalizations and a 38% decrease in cardiovascular mortality. Additionally, a meta-analysis of 31 randomized controlled trials indicated a 25% relative risk reduction in AF occurrences, with a similar decrease in the total number of AF episodes. Furthermore, another meta-analysis of 16 studies involving 38,335 patients demonstrated that the use of SGLT-2 inhibitors reduced the incidence of AF. In subgroup analyses of the DECLARE TIMI 58 (Dapagliflozin Effect on Cardiovascular Events – Thrombolysis In Myocardial Infarction 58) trial, which evaluated the cardiovascular safety of dapagliflozin, it was found that dapagliflozin reduced the risk of initial atrial fibrillation and atrial flutter (AFL) events by 19% and the total number of AF/AFL events by 23% during the follow-up period.

Various potential direct and indirect cardioprotective effects of SGLT2 inhibitors have been reported. Empagliflozin, in particular, has been shown to significantly reduce the volume of epicardial adipose tissue (EAT). This reduction is critical as EAT can induce fibrosis of the atrial myocardium by secreting adipofibrokines, thereby increasing susceptibility to atrial fibrillation (AF). Takano et al. provided evidence that SGLT2 inhibitors enhance cardioprotective effects on heart failure and atrial fibrillation specifically by reducing EAT in humans. Mechanisms including decreased body weight, enhanced osmotic diuresis and glucose excretion, reduced arterial blood pressure, myocardial remodeling, and delayed fibrosis formation are believed to play crucial roles in the pathophysiology that slows the development of AF in patients treated with SGLT-2 inhibitors.

Empagliflozin significantly lowered systolic blood pressure compared to placebo in the EMBOdy (Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus) study, which examined its impact on cardiac sympathetic activity in type 2 DM patients with acute myocardial infarction. However, the reduction in heart rate did not reach statistical significance. Conversely, another study found that tofogliflozin significantly lowered resting heart rate compared to placebo, independent of reductions in HbA1c, body weight, and blood pressure. In our study, we observed a decrease in the heart rate from an initial
83.9 ± 13.2 beats per minute to 76.5 ± 11.4 beats per minute after the use of SGLT-2 inhibitor (P < 0.001). The inconsistency between studies may be due to differences in the stability of coronary artery disease.

In a study by Aslan et al., 37 a significant decrease in right interatrial EMD times was noted with empagliflozin. They demonstrated that this change was correlated with a reduction in left atrial volume. In our study, we found that the initial left atrial volume measurements were smaller than those reported in the study by Aslan et al., 37 and there was no significant reduction in these values following treatment.

While SGLT-2 inhibitors positively influence the onset of new AF cases and recurrence, our review of the literature did not uncover any studies exploring the impact of this drug class on atrial EMD times associated with AF.

Our study noted a marked decrease in atrial electromyography (EMG) times when patients were treated with SGLT-2 inhibitors compared to baseline measurements. We believe that the reduced AF incidence in type 2 DM patients who use SGLT-2 inhibitors may be linked to this observation, suggesting it as a potential mechanism.

Conclusion

Our study demonstrated that 6-month treatment with SGLT-2 inhibitors led to improved interatrial conduction times and significantly reduced atrial EMD times in patients with type 2 DM. These reductions in atrial EMD times may serve as predictive markers for the onset of AF in this patient population. Our findings may help elucidate how SGLT-2 inhibitors benefit patients with type 2 DM by reducing the frequency and recurrence of AF. However, larger patient populations and extended follow-up periods are needed to support our study’s findings.

Ethics Committee Approval: This study received approval from the Medical Research Ethics Committee of Kahramanmaraş Sütçü İmam University (Approval Date: June 8, 2021; Approval Number: 2021/20).

Informed consent: Each patient provided written informed consent.

Peer-review: Externally peer-reviewed.


Use of AI for Writing Assistance: The authors declare that AI-assisted technologies were not used in this study.

Conflict of Interest: No conflicts of interest have been received from the authors.

Funding: The authors declared that this study received no financial support.

References


